Literature DB >> 20840346

Psoriasis and non-alcoholic fatty liver disease.

K S Wenk1, K C Arrington, A Ehrlich.   

Abstract

Several recent studies have found an increased prevalence of non-alcoholic fatty liver disease within psoriasis patients. The exact pathophysiological mechanisms behind these observations are unclear, but are likely related to the high prevalence of obesity and metabolic syndrome within this patient population. Chronic inflammation, mediated by either proinflammatory adipokines or skin-derived cytokines, may contribute to fatty liver disease development by increasing insulin resistance which in turn promotes hepatic lipid accumulation. These same adipokines in addition to hepatic cytokines may act on the skin to influence psoriasis disease severity.
© 2010 The Authors. Journal of the European Academy of Dermatology and Venereology © 2010 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840346     DOI: 10.1111/j.1468-3083.2010.03841.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  14 in total

Review 1.  Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Authors:  Giulia Ganzetti; Anna Campanati; Annamaria Offidani
Journal:  World J Hepatol       Date:  2015-03-27

2.  A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis.

Authors:  Olabola Awosika; Misty G Eleryan; Monica Rengifo-Pardo; Lindsay Doherty; Lisa W Martin; Alison Ehrlich
Journal:  J Clin Aesthet Dermatol       Date:  2018-06-01

Review 3.  Psoriasis and comorbidities: links and risks.

Authors:  Catherine Ni; Melvin W Chiu
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-04-17

Review 4.  Psoriasis: classical and emerging comorbidities.

Authors:  Maria de Fátima Santos Paim de Oliveira; Bruno de Oliveira Rocha; Gleison Vieira Duarte
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

5.  Development of autoimmune hepatitis in a psoriasis patient without immunosuppressive therapy.

Authors:  Wonyong Jo; Young-Sun Suh; Sang-Il Lee; Yun-Hong Cheon; Jeongmin Hong; Sang Su Lee; Ji Eun Kim; Gyung Hyuck Ko; Hyun-Ok Kim
Journal:  Clin Mol Hepatol       Date:  2017-05-08

Review 6.  Management of psoriasis as a systemic disease: what is the evidence?

Authors:  N J Korman
Journal:  Br J Dermatol       Date:  2019-10-15       Impact factor: 9.302

7.  Apoptosis and clinical severity in patients with psoriasis and HCV infection.

Authors:  Sami A Gabr; Mohamed Y Berika; Ahmad H Alghadir
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494

Review 8.  Psoriasis and inflammatory bowel disease: links and risks.

Authors:  Christoforos Vlachos; Georgios Gaitanis; Konstantinos H Katsanos; Dimitrios K Christodoulou; Epameinondas Tsianos; Ioannis D Bassukas
Journal:  Psoriasis (Auckl)       Date:  2016-07-20

Review 9.  NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome.

Authors:  Valerio Rosato; Mario Masarone; Marcello Dallio; Alessandro Federico; Andrea Aglitti; Marcello Persico
Journal:  Int J Environ Res Public Health       Date:  2019-09-14       Impact factor: 3.390

Review 10.  New insights into different adipokines in linking the pathophysiology of obesity and psoriasis.

Authors:  Yi Kong; Suhan Zhang; Ruifang Wu; Xin Su; Daoquan Peng; Ming Zhao; Yuwen Su
Journal:  Lipids Health Dis       Date:  2019-09-14       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.